Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

M. S. Aapro, F. H. van Wijk, G. Bolis, B. Chevallier, M. E L van der Burg, A. Poveda, C. F. de Oliveira, S. Tumolo, V. Scotto di Palumbo, M. Piccart, M. Franchi, F. Zanaboni, A. J. Lacave, R. Fontanelli, G. Favalli, P. Zola, J. P. Guastalla, R. Rosso, C. Marth, M. NooijM. Presti, C. Scarabelli, T. A W Splinter, E. Ploch, L. V A Beex, W. ten Bokkel Huinink, M. Forni, M. Melpignano, P. Blake, P. Kerbrat, C. Mendiola, A. Cervantes, A. Goupil, P. G. Harper, C. Madronal, M. Namer, G. Scarfone, J. E G M Stoot, I. Teodorovic, C. Coens, I. Vergote, J. B. Vermorken

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group'. Together they form a unique fingerprint.

Medicine & Life Sciences